

In the Claims

Please amend the claims as follows. A complete set of pending claims is presented below, with insertions indicated by underlining and deletions indicated by strikethrough.

1.-7. (Canceled)

8. (Currently amended) A method for stimulating an immune response in a HLA-B35 positive subject ~~enriching selectively a population of T lymphocytes with T lymphocytes specific for a MAGE-A1 HLA binding peptide~~, comprising:

administering to the subject a MAGE-A1 HLA-B35 binding peptide comprising SEQ ID NO:10 or contacting a source of T lymphocytes which contains a population of T lymphocytes with an agent presenting a complex of a MAGE-A1 HLA-B35 binding peptide comprising SEQ ID NO:10 and a HLA-B35 molecule or a complex of a MAGE-A1 HLA-B44 binding peptide comprising SEQ ID NO:53 and a HLA-B44 molecule, in an amount sufficient to stimulate an immune response ~~selectively enrich the population of T lymphocytes with the T lymphocytes specific for the MAGE-A1 HLA-B35 binding peptide or one of the complexes.~~

9. (Currently amended) The method of claim 8, wherein the agent is ~~selected from the group consisting of~~ an antigen presenting cell which expresses a HLA-B35 molecule contacted with a MAGE-A1 protein or a HLA binding fragment thereof which comprises SEQ ID NO:10; ~~and an antigen presenting cell which expresses a HLA-B44 molecule contacted with a MAGE-A1 protein or a HLA binding fragment thereof which comprises SEQ ID NO:53.~~

10.-78. (Canceled)

79. (New) The method of claim 8 wherein the MAGE-A1 HLA-B35 binding peptide is selected from the group consisting of (i) SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, and (ii) functional variants of the peptides of (i).

80. (New) The method of claim 8 wherein the MAGE-A1 HLA-B35 binding peptide is a fragment of SEQ ID NO:2 that comprises SEQ ID NO:10, and (ii) functional variants of the peptides of (i).
81. (New) The method of claim 8, further comprising administering an immune response potentiating compound.
82. (New) The method of claim 81, wherein the immune response potentiating compound is an adjuvant.
83. (New) The method of claim 81, wherein the immune response potentiating compound is a cytokine.
84. (New) The method of claim 8, wherein the stimulated immune response includes an increase in antibodies or T lymphocytes which are specific for the MAGE-A1 HLA-B35 binding peptide that is administered.
85. (New) The method of claim 8, further comprising administering to the subject at least one isolated HLA binding peptide selected from the group consisting of (1) MAGE-A1 HLA class I binding peptides other than peptides comprising SEQ ID NO:8, (2) MAGE-A1 HLA class II binding peptides, and (3) MAGE-A1 HLA class I or class II binding peptide of a non-MAGE-A1 tumor antigen, in an amount sufficient to stimulate an immune response.